Compare Ares Capital Corporation (ARCC) vs Cigna Corp (CI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ares Capital Corporation vs Cigna Corp — how do they compare? Ares Capital Corporation trades at $18.77 (market cap $13.48B), while Cigna Corp trades at $292.51 (market cap $77.63B). The key difference: Cigna Corp is far larger — about 5.8× Ares Capital Corporation's market cap, and Ares Capital Corporation pays the higher dividend (10.22%). Which is the better fit depends on your goals.
| ARCC | CI | |
|---|---|---|
Market Cap | $13.48B | $77.63B |
Sector | Financials | Health |
52-Week High | $23.25 | $311.00 |
52-Week Low | $17.45 | $244.41 |
Dividend Yield | 10.22% | 2.13% |
Enterprise Value | — | $100.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ares Capital (ARCC) trades at $18.78, up 2.01% on the day, with a bearish technical signal but strong analyst support. The stock shows a P/E of 11.52 and P/B of 0.96, trading below the consensus price target of $20.58. Recent earnings have missed expectations, with Q2 2026 results pending, while revenue declined to $1.51B in 2025 from $1.7B in 2024. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income appeal amid mixed sentiment.
ARCC presents a value opportunity with a high dividend yield and undervaluation relative to analyst targets, but faces headwinds from earnings misses and a bearish technical outlook. Risks include revenue volatility and competitive pressures in the BDC space, though institutional buy ratings suggest confidence in recovery potential. Investors should weigh income stability against growth challenges.
Cigna (CI) trades at $293.46, up 0.57% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.44 and P/S of 0.28. Recent news highlights strategic initiatives, including AI integration in pharmacy services. The current price is near the consensus price target of $339.82, indicating potential upside.
The outlook for CI is positive, driven by earnings momentum, a favorable analyst consensus, and strategic growth investments. Key risks include regulatory challenges, as seen in a recent lawsuit in Tennessee, and competitive pressures in the healthcare sector. Net cash flow turned negative in 2025, which warrants monitoring. The stock presents a value opportunity with a solid dividend, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
